WORTH THEIR WEIGHT? AN OVERVIEW OF THE INITIAL REIMBURSEMENT DECISIONS FOR GLP-1s IN THE EU5

被引：0
|
作者：
Tzaras, D. [1 ]
Macaulay, R. [1 ]
机构：
[1] Precis AQ, London, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA62
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 5 条
  • [1] INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION ...
    Walzer, S.
    Prada, M.
    Berard, I
    Benazet, F.
    Greenhill, W.
    Martinez, D.
    Vollmer, L.
    VALUE IN HEALTH, 2019, 22 : S424 - S424
  • [2] ACCESS AND REIMBURSEMENT FOR CURRENT AND EMERGING ALZHEIMER'S DISEASE-MODIFYING THERAPIES IN THE EU5
    Privolnev, Y.
    Blutstein, T.
    Cox, J.
    Reyes, A.
    VALUE IN HEALTH, 2018, 21 : S344 - S344
  • [3] COMPARISON OF EU5 MARKET ACCESS DECISIONS FOR CROHN'S DISEASE BASED ON THE PRISMACCESS® DATABASE
    Vollmer, L. M.
    de Paz, B.
    Schleich, W.
    Walzer, S.
    VALUE IN HEALTH, 2018, 21 : S465 - S465
  • [4] UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERS
    Singh, Kumar K.
    Clapton, G. S.
    de Sousa, Rebelo C.
    Tripathi, S.
    VALUE IN HEALTH, 2018, 21 : S192 - S192
  • [5] Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting
    Coleman, Craig I.
    Herman, William H.
    Pandya, Shivani
    Wang, Li
    Baser, Onur
    Cai, Jennifer
    Bookhart, Brahim
    DIABETES, 2018, 67
1